{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:38:19Z","timestamp":1793291899780,"version":"4.5.0"},"reference-count":188,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT202895"],"award-info":[{"award-number":["GNT202895"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT11234999"],"award-info":[{"award-number":["GNT11234999"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["R01HG010863"],"award-info":[{"award-number":["R01HG010863"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIH NIAID","doi-asserted-by":"publisher","award":["U01AI154659"],"award-info":[{"award-number":["U01AI154659"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R13AR074889"],"award-info":[{"award-number":["R13AR074889"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI152183"],"award-info":[{"award-number":["R01AI152183"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.alit.2025.05.002","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T15:49:40Z","timestamp":1749052180000},"page":"361-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Updates in the pathogenesis of SJS\/TEN"],"prefix":"10.1016","volume":"74","author":[{"given":"Joy","family":"Justice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Martin-Pozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2025.05.002_bib1","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.alit.2025.05.002_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib3","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","article-title":"The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification","volume":"102","author":"Roujeau","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib4","article-title":"Characterization of demographics, drug latency, and mortality of severe cutaneous adverse reactions in an FDA pharmacovigilance database","author":"Mukherjee","year":"2025","journal-title":"medRxiv [preprint]."},{"key":"10.1016\/j.alit.2025.05.002_bib5","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed\/MEDLINE case reports from 1980 to 2020","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.alit.2025.05.002_bib6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","article-title":"Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"159","author":"Lee","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.588063","article-title":"Current pharmacogenetic perspective on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"12","author":"Cheng","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.alit.2025.05.002_bib8","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/1346-8138.15493","article-title":"Toxic epidermal necrolysis induced by human herpesvirus 7 treated with a tumor necrosis factor-\u03b1 inhibitor","volume":"47","author":"Shen","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jaad.2021.04.066","article-title":"Mycoplasma-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis: case-control analysis of a cohort managed in a specialized center","volume":"86","author":"Liew","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/bjd\/ljad226","article-title":"Comparison of idiopathic and drug-induced epidermal necrolysis in children","volume":"189","author":"Welfringer-Morin","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","article-title":"The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib12","article-title":"Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using national Health insurance database in Korea","volume":"11","author":"Yang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.alit.2025.05.002_bib13","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jid.2017.01.031","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK","volume":"137","author":"Frey","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(96)00035-2","article-title":"Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry","volume":"49","author":"Rzany","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.alit.2025.05.002_bib16","article-title":"The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in China","volume":"2018","author":"Yang","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.alit.2025.05.002_bib17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archderm.1991.01680050083008","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany","volume":"127","author":"Sch\u00f6pf","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-024-00514-0","article-title":"Severe cutaneous adverse reactions","volume":"10","author":"Hung","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.alit.2025.05.002_bib19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/bjd.18424","article-title":"Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome\/toxic epidermal necrolysis) in France during 2003-16: a four-source capture-recapture estimate","volume":"182","author":"Chaby","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jid.2023.09.274","article-title":"Validation of an algorithm to identify epidermal necrolysis on a medico-administrative database","volume":"144","author":"Bettuzzi","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40257-021-00661-0","article-title":"Culprit medications and risk factors associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: population-based nested case-control study","volume":"23","author":"Gronich","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib22","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/ced\/llae183","article-title":"Risk factors for the development of Stevens-Johnson syndrome\/toxic epidermal necrolysis following drug administration: a systematic review and meta-analysis","volume":"49","author":"Fathima","year":"2024","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib24","doi-asserted-by":"crossref","unstructured":"Jha KK, Chaudhary DP, Rijal T, Dahal S. Delayed Stevens-Johnson syndrome secondary to the use of lamotrigine in bipolar mood disorder. Indian J Psychol Med. 39:209-12.","DOI":"10.4103\/0253-7176.203130"},{"key":"10.1016\/j.alit.2025.05.002_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5415\/apallergy.2014.4.1.68","article-title":"Rapid onset of Stevens-Johnson syndrome and toxic epidermal necrolysis after ingestion of acetaminophen","volume":"4","author":"Kim","year":"2014","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.alit.2025.05.002_bib26","article-title":"Rapidly developing toxic epidermal necrolysis","volume":"2013","author":"Poulsen","year":"2013","journal-title":"Case Rep Emerg Med"},{"key":"10.1016\/j.alit.2025.05.002_bib27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1078155213518226","article-title":"Late onset imatinib-induced Stevens-Johnson syndrome","volume":"20","author":"Bois","year":"2014","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.alit.2025.05.002_bib28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-024-00889-6","article-title":"Update on Stevens-Johnson syndrome and toxic epidermal necrolysis: diagnosis and management","volume":"25","author":"Shah","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/wound.2019.0977","article-title":"Toxic epidermal necrolysis and steven-johnson syndrome: a comprehensive review","volume":"9","author":"Charlton","year":"2020","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"10.1016\/j.alit.2025.05.002_bib30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/INF.0000000000001571","article-title":"Fever in Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric cases: laboratory work-up and antibiotic therapy","volume":"36","author":"Paulmann","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.alit.2025.05.002_bib31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40629-019-00111-8","article-title":"Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment","volume":"28","author":"Paulmann","year":"2019","journal-title":"Allergo J Int"},{"key":"10.1016\/j.alit.2025.05.002_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jdin.2023.06.014","article-title":"Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome","volume":"13","author":"Wasuwanich","year":"2023","journal-title":"JAAD Int"},{"key":"10.1016\/j.alit.2025.05.002_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13601-015-0073-8","article-title":"Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back","volume":"5","author":"Schrijvers","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.alit.2025.05.002_bib34","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/all.15889","article-title":"Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper","volume":"78","author":"Jutel","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.05.002_bib35","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.alit.2025.05.002_bib36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1523-1747.2000.00105.x","article-title":"T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic","volume":"115","author":"Yawalkar","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib38","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib39","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40812-3","article-title":"Correlations between histopathologic findings, serum biomarker levels, and clinical outcomes in Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN)","volume":"13","author":"Chuenwipasakul","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.alit.2025.05.002_bib41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.molimm.2019.01.002","article-title":"Comprehensive assessment of T cell receptor \u03b2 repertoire in Stevens-Johnson syndrome\/toxic epidermal necrolysis patients using high-throughput sequencing","volume":"106","author":"Xiong","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.654190","article-title":"Skin resident memory T cells may play critical role in delayed-type drug hypersensitivity reactions","volume":"12","author":"Schunkert","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib43","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1016\/j.jaad.2014.07.013","article-title":"Toxic epidermal necrolysis in the absence of circulating T cells: a possible role for resident memory T cells","volume":"71","author":"Iriki","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib44","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1038\/s41467-024-52990-3","article-title":"Multiomic single-cell sequencing defines tissue-specific responses in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"15","author":"Gibson","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.alit.2025.05.002_bib45","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/pgs.12.108","article-title":"HLA and pharmacogenetics of drug hypersensitivity","volume":"13","author":"Pavlos","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.alit.2025.05.002_bib46","first-page":"12","article-title":"Hypersensitivity reactions to \u03b2-lactams: relevance of hapten-protein conjugates","volume":"25","author":"Ariza","year":"2015","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib47","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nri3150","article-title":"Early immune events in the induction of allergic contact dermatitis","volume":"12","author":"Kaplan","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5415\/apallergy.2016.6.2.77","article-title":"T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance","volume":"6","author":"Yun","year":"2016","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.alit.2025.05.002_bib49","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2007.06.017","article-title":"HLA-B\u22171502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome","volume":"120","author":"Yang","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib50","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.4049\/jimmunol.1302306","article-title":"Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B\u221758:01","volume":"192","author":"Yun","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib51","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nature11147","article-title":"Immune self-reactivity triggered by drug-modified HLA-peptide repertoire","volume":"486","author":"Illing","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.alit.2025.05.002_bib52","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008227","article-title":"An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions","volume":"6","author":"Saito","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.alit.2025.05.002_bib54","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jid.2022.11.024","article-title":"TNF-\u03b1\u2012Mediated keratinocyte expression and release of matrix metalloproteinase 9: putative mechanism of pathogenesis in Stevens\u2012Johnson syndrome\/toxic epidermal necrolysis","volume":"143","author":"Olsson-Brown","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1600-0625.2010.01176.x","article-title":"Death ligand TRAIL, secreted by CD1a+ and CD14+ cells in blister fluids, is involved in killing keratinocytes in toxic epidermal necrolysis","volume":"20","author":"de Araujo","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib56","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/08820538.2015.1115255","article-title":"Immunologic mediators in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"31","author":"Saeed","year":"2016","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.alit.2025.05.002_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2398","article-title":"Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"13","author":"Kinoshita","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.alit.2025.05.002_bib58","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2133.2011.10649.x","article-title":"Possible involvement of CD14+ CD16+ monocyte lineage cells in the epidermal damage of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"166","author":"Tohyama","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib59","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41586-024-08061-0","article-title":"Spatial proteomics identifies JAKi as treatment for a lethal skin disease","volume":"635","author":"Nordmann","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.alit.2025.05.002_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147527","article-title":"Diagnostic tools and biomarkers for severe drug eruptions","volume":"22","author":"Yoshioka","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.alit.2025.05.002_bib61","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0092-8674(00)81874-7","article-title":"Apoptosis by death factor","volume":"88","author":"Nagata","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.alit.2025.05.002_bib62","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","article-title":"Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment","volume":"122","author":"Murata","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib63","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ajd.14329","article-title":"A systematic review of case-control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis","volume":"65","author":"Stewart","year":"2024","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib64","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.alit.2025.05.002_bib65","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2340\/00015555-0074","article-title":"Diagnostic role of soluble fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering disease: a pilot study","volume":"86","author":"Lan","year":"2006","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.alit.2025.05.002_bib66","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature09518","article-title":"The structural basis for membrane binding and pore formation by lymphocyte perforin","volume":"468","author":"Law","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.alit.2025.05.002_bib67","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/335448a0","article-title":"Structure and function of human perforin","volume":"335","author":"Lichtenheld","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.alit.2025.05.002_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031833","article-title":"Granzymes: the molecular executors of immune-mediated cytotoxicity","volume":"23","author":"Hay","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.alit.2025.05.002_bib69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mai.2002.120563","article-title":"Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity","volume":"109","author":"Posadas","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib70","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4049\/jimmunol.167.1.350","article-title":"A distinct pathway of cell-mediated apoptosis initiated by granulysin","volume":"167","author":"Kaspar","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib71","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620950831","article-title":"The role of IL-13, IL-15 and granulysin in the pathogenesis of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"27","author":"Sadek","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.alit.2025.05.002_bib72","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jaip.2020.09.048","article-title":"Detecting lesional granulysin levels for rapid diagnosis of cytotoxic T lymphocyte-mediated bullous skin disorders","volume":"9","author":"Chen","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.05.002_bib73","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.alit.2025.05.002_bib74","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1038\/jid.2015.159","article-title":"RIPping the skin apart: necroptosis signaling in toxic epidermal necrolysis","volume":"135","author":"Panayotova-Dimitrova","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature14191","article-title":"Necroptosis and its role in inflammation","volume":"517","author":"Pasparakis","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.alit.2025.05.002_bib76","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1310050","article-title":"Necroptosis","volume":"370","author":"Linkermann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2025.05.002_bib77","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/bjd\/ljae321","article-title":"Recent progress in Stevens-Johnson syndrome\/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment","volume":"192","author":"Hama","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib78","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3889\/oamjms.2022.10337","article-title":"High serum level of TNF-\u03b1 in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"10","author":"Huyen","year":"2022","journal-title":"Open Access Macedonian J Med Sci"},{"key":"10.1016\/j.alit.2025.05.002_bib79","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13601-018-0199-6","article-title":"Diverse expression of TNF-\u03b1 and CCL27 in serum and blister of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"8","author":"Wang","year":"2018","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.alit.2025.05.002_bib80","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2133.2006.07398.x","article-title":"Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"155","author":"Caproni","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib81","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/1346-8138.16847","article-title":"TNF-\u03b1 induced extracellular release of keratinocyte high-mobility group box 1 in Stevens-Johnson syndrome\/toxic epidermal necrolysis: biomarker and putative mechanism of pathogenesis","volume":"50","author":"Nwikue","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib82","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00403-004-0506-z","article-title":"Possible involvement of gelatinase A (MMP2) and gelatinase B (MMP9) in toxic epidermal necrolysis or Stevens-Johnson syndrome","volume":"296","author":"Gaultier","year":"2004","journal-title":"Arch Dermatol Res"},{"issue":"Pt 1","key":"10.1016\/j.alit.2025.05.002_bib83","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1042\/bj2770277","article-title":"Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP)","volume":"277","author":"Murphy","year":"1991","journal-title":"Biochem J"},{"key":"10.1016\/j.alit.2025.05.002_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12964-021-00730-1","article-title":"The exosome journey: from biogenesis to uptake and intracellular signalling","volume":"19","author":"Gurung","year":"2021","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.alit.2025.05.002_bib85","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13578-019-0282-2","article-title":"Exosomes: biogenesis, biologic function and clinical potential","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell Biosci"},{"key":"10.1016\/j.alit.2025.05.002_bib86","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jaci.2013.09.019","article-title":"Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions","volume":"133","author":"Ichihara","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw6142","article-title":"Plasma exosomal miR-375-3p regulates mitochondria-dependent keratinocyte apoptosis by targeting XIAP in severe drug-induced skin reactions","volume":"12","author":"Zhang","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.alit.2025.05.002_bib88","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1111\/jdv.19000","article-title":"Exosomal microRNAs from PBMCs stimulated with culprit drugs enhanced keratinocyte cell death in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"37","author":"Suthumchai","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2025.05.002_bib89","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib90","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3390\/biomedicines10081868","article-title":"IL-15\/IL-15R\u03b1 in SJS\/TEN: relevant expression of IL15 and IL15RA in affected skin","volume":"10","author":"Bell\u00f3n","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.alit.2025.05.002_bib91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1067\/mjd.2002.120473","article-title":"Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis","volume":"47","author":"Correia","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib92","first-page":"3875","article-title":"The potential roles of IL-6 and NKG2C in the pathogenesis of Stevens Johnson syndrome\/toxic epidermal necrolysis","volume":"63","author":"Iqbal","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.alit.2025.05.002_bib93","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1038\/s41598-021-85009-8","article-title":"High S100A2 expression in keratinocytes in patients with drug eruption","volume":"11","author":"Yoshioka","year":"2021","journal-title":"Scientific Rep"},{"key":"10.1016\/j.alit.2025.05.002_bib94","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol Rev"},{"key":"10.1016\/j.alit.2025.05.002_bib95","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jaci.2024.10.015","article-title":"Sensory neuroimmune signaling in the pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"155","author":"Huang","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.634607","article-title":"NLRP3 inflammasome: a promising therapeutic target for drug-induced toxicity","volume":"9","author":"Wei","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.alit.2025.05.002_bib97","first-page":"10","article-title":"The role of NLRP3 inflammasome in the pathogenesis of Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"12","author":"Shekhar","year":"2024","journal-title":"Med Res Arch"},{"key":"10.1016\/j.alit.2025.05.002_bib98","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s43556-023-00151-1","article-title":"JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions","volume":"4","author":"Sarapultsev","year":"2023","journal-title":"Mol Biomed"},{"key":"10.1016\/j.alit.2025.05.002_bib99","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1750-1172-6-52","article-title":"Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in europe","volume":"6","author":"G\u00e9nin","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.alit.2025.05.002_bib100","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/cts.12787","article-title":"Associations of CYP2C9 and CYP2C19 pharmacogenetic variation with phenytoin-induced cutaneous adverse drug reactions","volume":"13","author":"Fohner","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.alit.2025.05.002_bib101","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00228-013-1549-x","article-title":"Association between CYP2B6 polymorphisms and Nevirapine-induced SJS\/TEN: a pharmacogenetics study","volume":"69","author":"Ciccacci","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.alit.2025.05.002_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131038","article-title":"ABC transporters and the proteasome complex are implicated in susceptibility to Stevens-Johnson syndrome and toxic epidermal necrolysis across multiple drugs","volume":"10","author":"Nicoletti","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.alit.2025.05.002_bib103","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jaci.2011.12.990","article-title":"Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome","volume":"129","author":"Wei","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib104","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.yebeh.2010.08.007","article-title":"Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B\u22171502 allele among patients in central China","volume":"19","author":"Wu","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.alit.2025.05.002_bib105","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/clpt.2013.55","article-title":"HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children","volume":"94","author":"Amstutz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.alit.2025.05.002_bib106","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.alit.2025.05.002_bib107","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdermsci.2013.10.003","article-title":"Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations","volume":"73","author":"Hsiao","year":"2014","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.alit.2025.05.002_bib108","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eplepsyres.2011.08.010","article-title":"Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans","volume":"97","author":"Kim","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.alit.2025.05.002_bib109","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B\u22171502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.alit.2025.05.002_bib110","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B\u22171502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.alit.2025.05.002_bib111","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FPC.0000000000000287","article-title":"HLA-A\u221731: 01 and HLA-B\u221715:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population","volume":"27","author":"Khor","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.alit.2025.05.002_bib112","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5415\/apallergy.2015.5.2.68","article-title":"HLA-B\u22171502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese","volume":"5","author":"Nguyen","year":"2015","journal-title":"Asia Pac Allergy"},{"key":"10.1016\/j.alit.2025.05.002_bib113","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000003453","article-title":"Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.alit.2025.05.002_bib114","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FPC.0000000000000211","article-title":"Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population","volume":"26","author":"Tassaneeyakul","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.alit.2025.05.002_bib115","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/tpj.2016.10","article-title":"Association of HLA-B\u221715:13 and HLA-B\u221715:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population","volume":"17","author":"Chang","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.alit.2025.05.002_bib116","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cpt.1190","article-title":"HLA alleles and CYP2C9\u22173 as predictors of phenytoin hypersensitivity in East asians","volume":"105","author":"Su","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.alit.2025.05.002_bib117","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.alit.2025.05.002_bib118","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/all.13821","article-title":"HLA-B\u221757:01 confers genetic susceptibility to carbamazepine-induced SJS\/TEN in Europeans","volume":"74","author":"Mockenhaupt","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2025.05.002_bib119","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fphar.2016.00186","article-title":"HLA-B (\u2217) 58:01 for allopurinol-induced cutaneous adverse drug reactions: implication for clinical interpretation in Thailand","volume":"7","author":"Sukasem","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.alit.2025.05.002_bib120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/FPC.0000000000000285","article-title":"Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population","volume":"27","author":"Saksit","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.alit.2025.05.002_bib121","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.13688","article-title":"HLA-B\u221758:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study","volume":"173","author":"Cheng","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib122","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1515\/cclm-2014-0251","article-title":"Detection of HLA-B\u221758:01 with TaqMan assay and its association with allopurinol-induced sCADR","volume":"53","author":"Zhang","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.alit.2025.05.002_bib123","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/FPC.0b013e32834282b8","article-title":"Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans","volume":"21","author":"Kang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.alit.2025.05.002_bib124","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjd.12389","article-title":"HLA-B\u221758:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Portuguese population","volume":"169","author":"Gon\u00e7alo","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib125","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.alit.2025.05.002_bib126","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","article-title":"Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians","volume":"147","author":"Wang","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib127","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/cid\/cit021","article-title":"Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population","volume":"56","author":"Carr","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.alit.2025.05.002_bib128","doi-asserted-by":"crossref","first-page":"4862","DOI":"10.1038\/srep04862","article-title":"Independent strong association of HLA-A\u221702:06 and HLA-B\u221744:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement","volume":"4","author":"Ueta","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.alit.2025.05.002_bib129","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1038\/srep05981","article-title":"Trans-ethnic study confirmed independent associations of HLA-A\u221702:06 and HLA-B\u221744:03 with cold medicine-related Stevens-Johnson syndrome with severe ocular surface complications","volume":"4","author":"Ueta","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.alit.2025.05.002_bib130","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s00198-016-3568-9","article-title":"Increased risk of strontium ranelate-related SJS\/TEN is associated with HLA","volume":"27","author":"Lee","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.alit.2025.05.002_bib131","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/jdv.16924","article-title":"The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA","volume":"35","author":"Chen","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2025.05.002_bib132","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamadermatol.2013.4114","article-title":"Relationship between the HLA-B\u22171502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"149","author":"Tangamornsuksan","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib133","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1001\/jama.2014.7859","article-title":"Genetic variants associated with phenytoin-related severe cutaneous adverse reactions","volume":"312","author":"Chung","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.alit.2025.05.002_bib134","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/jcpt.12660","article-title":"Association of CYP2C9\u22173 with phenytoin-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"43","author":"Wu","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.alit.2025.05.002_bib135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2007.08.036","article-title":"Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel","volume":"58","author":"Halevy","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib136","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B\u22175801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.alit.2025.05.002_bib137","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B\u22175801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.alit.2025.05.002_bib138","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol","volume":"46","author":"Day","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.alit.2025.05.002_bib139","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.alit.2025.05.002_bib140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/jat.3522","article-title":"Allopurinol suppresses expression of the regulatory T-cell migration factors TARC\/CCL17 and MDC\/CCL22 in HaCaT keratinocytes via restriction of nuclear factor-\u03baB activation","volume":"38","author":"Osabe","year":"2018","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.alit.2025.05.002_bib141","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2125.2003.01754.x","article-title":"Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity","volume":"55","author":"Alfirevic","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.alit.2025.05.002_bib142","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00008571-199508000-00011","article-title":"A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Wolkenstein","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.alit.2025.05.002_bib143","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00008571-200011000-00005","article-title":"Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity","volume":"10","author":"Pirmohamed","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.alit.2025.05.002_bib144","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/clpt.1991.3","article-title":"Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions","volume":"49","author":"Rieder","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.alit.2025.05.002_bib145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2165\/11593240-000000000-00000","article-title":"Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study","volume":"13","author":"Mittmann","year":"2012","journal-title":"Am J Clin Dermatol"},{"issue":"1 Suppl","key":"10.1016\/j.alit.2025.05.002_bib146","first-page":"e366","article-title":"The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8+ T cells in HIV-1-infected typical progressors, but not in long-term non-progressors","volume":"128","author":"Jiao","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.alit.2025.05.002_bib147","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3389\/fimmu.2017.00580","article-title":"Pathophysiology of CD4+ T-cell depletion in HIV-1 and HIV-2 infections","volume":"8","author":"Vidya Vijayan","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib148","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1172\/JCI99321","article-title":"A transgenic mouse model for HLA-B\u221757:01-linked abacavir drug tolerance and reactivity","volume":"128","author":"Cardone","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.alit.2025.05.002_bib149","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1172\/JCI121525","article-title":"Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B\u221757:01 peptide repertoire alteration","volume":"128","author":"Phillips","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.alit.2025.05.002_bib150","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620905998","article-title":"Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017","volume":"11","author":"Oshikoya","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.alit.2025.05.002_bib151","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00228-017-2295-2","article-title":"Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS\/TEN susceptibility","volume":"73","author":"Ciccacci","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.alit.2025.05.002_bib152","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.3390\/ijms16035830","article-title":"A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS\/TEN susceptibility","volume":"16","author":"Ciccacci","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.alit.2025.05.002_bib153","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.preteyeres.2012.05.003","article-title":"Ocular surface inflammation is regulated by innate immunity","volume":"31","author":"Ueta","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.alit.2025.05.002_bib154","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tjo.2016.06.001","article-title":"Cold medicine-related Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications-phenotypes and genetic predispositions","volume":"6","author":"Ueta","year":"2016","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.alit.2025.05.002_bib155","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaci.2010.08.007","article-title":"Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study","volume":"126","author":"Ueta","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib156","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jaci.2014.12.1916","article-title":"IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe mucosal involvement","volume":"135","author":"Ueta","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib157","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41525-021-00171-2","article-title":"Mapping of susceptible variants for cold medicine-related Stevens-Johnson syndrome by whole-genome resequencing","volume":"6","author":"Kawai","year":"2021","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.alit.2025.05.002_bib158","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaip.2017.10.033","article-title":"Epidermal necrolysis, ocular complications, and \u201ccold medicines\u201d","volume":"6","author":"Roujeau","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.05.002_bib159","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.2147\/JIR.S491791","article-title":"Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor versus non-immune checkpoint inhibitor drugs in China: a cross-sectional study and literature review","volume":"17","author":"Qin","year":"2024","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.alit.2025.05.002_bib160","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1346-8138.17039","article-title":"Immune checkpoint inhibitor-induced epidermal necrolysis: a narrative review evaluating demographics, clinical features, and culprit medications","volume":"51","author":"Satoh","year":"2024","journal-title":"J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib161","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib162","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54180-7","article-title":"Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.alit.2025.05.002_bib163","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jaad.2020.03.029","article-title":"Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series","volume":"83","author":"Molina","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib164","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/ddg.13876","article-title":"Severe bullous skin eruptions on checkpoint inhibitor therapy - in most cases severe bullous lichenoid drug eruptions","volume":"17","author":"Reschke","year":"2019","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.alit.2025.05.002_bib165","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00403-024-03061-6","article-title":"Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases","volume":"316","author":"Bray","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.alit.2025.05.002_bib166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0477","article-title":"Steven-Johnson syndrome\/toxic epidermal necrolysis is associated with PD-1\/PD-L1 inhibitors usage: a case series","volume":"85","author":"Cao","year":"2024","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.alit.2025.05.002_bib167","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1056\/NEJMoa1009717","article-title":"Carbamazepine-induced toxic effects and HLA-B\u22171502 screening in Taiwan","volume":"364","author":"Chen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2025.05.002_bib168","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1212\/WNL.0b013e31826aac73","article-title":"Cost-effectiveness of HLA-B\u22171502 genotyping in adult patients with newly diagnosed epilepsy in Singapore","volume":"79","author":"Dong","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.alit.2025.05.002_bib169","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11096-013-9777-9","article-title":"Cost minimization of HLA-B\u22171502 screening before prescribing carbamazepine in Thailand","volume":"35","author":"Tiamkao","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.alit.2025.05.002_bib170","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/epi.12325","article-title":"Economic evaluation of HLA-B\u221715:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand","volume":"54","author":"Rattanavipapong","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.alit.2025.05.002_bib171","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/FPC.0000000000000319","article-title":"Cost-effectiveness analysis of HLA-B\u221758: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis in a Malaysian population","volume":"28","author":"Chong","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.alit.2025.05.002_bib172","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/1203475419867599","article-title":"HLA-B\u221758:01 genotyping to prevent cases of DRESS and SJS\/TEN in East asians treated with allopurinol-A Canadian missed opportunity","volume":"23","author":"Ponzo","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.alit.2025.05.002_bib173","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.jaip.2020.07.005","article-title":"Delabeling delayed drug hypersensitivity: how far can you safely go?","volume":"8","author":"Lehloenya","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.05.002_bib174","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2025.05.002_bib175","article-title":"Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions","volume":"9","author":"Copaescu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.alit.2025.05.002_bib176","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaip.2022.01.038","article-title":"Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: a multicenter observational study","volume":"10","author":"Zhang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2025.05.002_bib177","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.alit.2025.05.002_bib178","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.alit.2025.05.002_bib179","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/09546634.2019.1577548","article-title":"Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review","volume":"31","author":"Zhang","year":"2020","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.alit.2025.05.002_bib180","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231223059","article-title":"Tumor necrosis factor-\u03b1 inhibitor for successful treatment of toxic epidermal necrolysis with severe infection: a case series","volume":"52","author":"Peng","year":"2024","journal-title":"J Int Med Res"},{"key":"10.1016\/j.alit.2025.05.002_bib181","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2020.08.122","article-title":"Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis","volume":"84","author":"Tsai","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib182","article-title":"Recent dermatological treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan","volume":"8","author":"Hsieh","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.alit.2025.05.002_bib183","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1060028014560012","article-title":"Corticosteroids in Stevens-Johnson syndrome\/toxic epidermal necrolysis:current evidence and implications for future research","volume":"49","author":"Law","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.alit.2025.05.002_bib184","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib185","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.alit.2025.05.002_bib186","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib187","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing No benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.alit.2025.05.002_bib188","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/1346-8138.12925","article-title":"Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"42","author":"Aihara","year":"2015","journal-title":"The J Dermatol"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893025000528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893025000528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:49:08Z","timestamp":1762368548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893025000528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":188,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1323893025000528"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2025.05.002","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in the pathogenesis of SJS\/TEN","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2025.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Allergology. Published by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}